Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease

被引：167

作者：

Andersson, Helena ^{[1
,2
]}

Sem, Marthe ^{[2
]}

Lund, May Brit ^{[3
]}

Aalokken, Trond Mogens ^{[4
]}

Gunther, Anne ^{[4
]}

Walle-Hansen, Ragnhild ^{[5
]}

Garen, Torhild ^{[2
]}

Molberg, Oyvind ^{[1
,2
]}

机构：

[1] Oslo Univ Hosp, Inst Clin Med, N-0424 Oslo, Norway

[2] Oslo Univ Hosp, Dept Rheumatol, N-0424 Oslo, Norway

[3] Oslo Univ Hosp, Dept Resp Med, N-0424 Oslo, Norway

[4] Oslo Univ Hosp, Dept Radiol, N-0424 Oslo, Norway

[5] Oslo Univ Hosp, Dept Orthopaed Surg, Oslo, Norway

来源：

RHEUMATOLOGY | 2015年 / 54卷 / 08期

关键词：

rituximab; anti-synthetase syndrome; myositis; anti-aminoacyl tRNA synthetase; anti-Jo1; interstitial lung disease; IDIOPATHIC INFLAMMATORY MYOPATHIES; RESOLUTION COMPUTED-TOMOGRAPHY; JUVENILE DERMATOMYOSITIS; PULMONARY-FIBROSIS; REFRACTORY ADULT; POLYMYOSITIS; THERAPY; AUTOANTIBODIES; PNEUMONIA; SURVIVAL;

D O I：

10.1093/rheumatology/kev004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To retrospectively evaluate the efficacy and safety of rituximab (Rtx) treatment in patients with anti-synthetase syndrome (ASS) and severe interstitial lung disease (ILD). Methods. Patients with severe ILD and > 12 months follow-up post-Rtx were identified from the Oslo University Hospital ASS cohort (n = 112). Clinical data, including pulmonary function tests (PFTs), were retrospectively collected from medical reports. Extent of ILD pre-, and post-Rtx was scored on thin-section high-resolution CT (HRCT) images and expressed as a percentage of total lung volume. Muscle strength was evaluated by manual muscle testing of eight muscle groups (MMT8). Results. Altogether, 34/112 ASS patients had received Rtx; 24/34 had severe ILD and > 12 months follow-up post-Rtx (median 52 months). In these 24 patients, the median percentage of predicted forced vital capacity, forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) increased by 24%, 22% and 17%, respectively, post-Rtx. Seven patients (all with disease duration < 12 months and/or acute onset/exacerbation of ILD) had > 30% improvement in all three PFTs. HRCT analysis showed a median 34% reduction in ILD extent post-Rtx. MMT8 score increased post-Rtx. During follow-up, 7/34 (21%) Rtx-treated ASS patients died; 6/7 deaths were related to infections. The mortality rate in the Rtx-treated group was comparable to that of the remaining ASS cohort (25/78 deceased; 32%). Conclusion. This study, which included 24 Rtx-treated ASS patients with severe ILD, reports improved PFTs after a median 52 months follow-up post-Rtx. The best outcome was observed in patients with a disease duration < 12 months and/or acute onset/exacerbation of ILD. The study indicates that Rtx could be a treatment option for selected ASS patients, but infections should be given attention. Key words: rituximab, anti-synthetase syndrome, myositis, anti-aminoacyl tRNA

引用

页码：1420 / 1428

页数：9

共 50 条

[31] Diffuse interstitial lung disease revealing anti-synthetase syndrome: about two cases [J].

El Bouardi, Nizar ;

Alaoui, Amina ;

Haloua, Meriem ;

Lamrani, Youssef ;

Boubbou, Meryem ;

Maaroufi, Mustapha ;

Alami, Baderdine .

PAN AFRICAN MEDICAL JOURNAL, 2019, 32

[32] Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome [J].

Hui Liu ;

Sheng Xie ;

Tian Liang ;

Li Ma ;

Hongliang Sun ;

Huaping Dai ;

Chen Wang .

European Radiology, 2019, 29 :5349-5357

[33] Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome [J].

Yamakawa, Hideaki ;

Hagiwara, Eri ;

Iwasawa, Tae ;

Otoshi, Ryota ;

Tabata, Erina ;

Ikeda, Satoshi ;

Okuda, Ryo ;

Baba, Tomohisa ;

Iso, Shinichiro ;

Okudela, Koji ;

Takemura, Tamiko ;

Sato, Shinji ;

Ogura, Takashi .

JOURNAL OF THORACIC DISEASE, 2018, 10 (10) :5924-5931

[34] Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies [J].

Yamakawa, Hideaki ;

Hagiwara, Eri ;

Kitamura, Hideya ;

Iwasawa, Tae ;

Otoshi, Ryota ;

Aiko, Naoto ;

Katano, Takuma ;

Shintani, Ryota ;

Ikeda, Satoshi ;

Okuda, Ryo ;

Sekine, Akimasa ;

Baba, Tomohisa ;

Iso, Shinichiro ;

Kuwano, Kazuyoshi ;

Sato, Shinji ;

Ogura, Takashi .

RESPIRATION, 2018, 96 (03) :210-221

[35] Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China [J].

Zhan, Xi ;

Yan, Wei ;

Wang, Ying ;

Li, Qing ;

Shi, Xuhua ;

Gao, Yanli ;

Ye, Qiao .

BMC PULMONARY MEDICINE, 2021, 21 (01)

[36] Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China [J].

Xi Zhan ;

Wei Yan ;

Ying Wang ;

Qing Li ;

Xuhua Shi ;

Yanli Gao ;

Qiao Ye .

BMC Pulmonary Medicine, 21

[37] Clinical-imaging characteristics and management of anti-JO-1 and non-JO-1 anti-synthetase syndrome-associated interstitial lung disease [J].

Zhou, Wanqing ;

Chen, Ranxun ;

Chen, Xi ;

Xie, Weiwei ;

Xu, Qingqing ;

Liu, Yin ;

Chen, Lulu ;

Chen, Bi ;

Dai, Jinghong .

RHEUMATOLOGY, 2025,

[38] Prevalence of Anti-Synthetase Syndrome in Patients of Interstitial Lung Disease with Connective Tissue Diseases and Autoimmune Features: A Cross-Sectional Study [J].

Indu, M. B. ;

Deepak, Desh ;

Bhatta, Ajay ;

Lalwani, Gunjan ;

Sharma, Brijesh ;

Somayya, Vardhini ;

Chhabra, Mala ;

Duggal, Nandini .

MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2025, 36 (01) :107-115

[39] Clinical experience in anti-synthetase syndrome: a monocentric retrospective analytical study [J].

Maloir, Quentin ;

Laurence, Seidel ;

Christian, Von Frenckell ;

Fanny, Gester ;

Renaud, Louis ;

Julien, Guiot .

ACTA CLINICA BELGICA, 2022, 77 (03) :624-630

[40] Refractory anti-synthetase syndrome treated with rituximab [J].

Ball, Elisabeth M. A. ;

Savage, Eimear M. ;

Pendleton, Adrian .

RHEUMATOLOGY, 2010, 49 (05) :1013-1013

← 1 2 3 4 5 →